Paragon 28 Inc is a medical device company focused on advancing innovation in the field of foot and ankle surgery
The company specializes in the development and commercialization of an extensive range of surgical implants and instruments designed to enhance patient outcomes and support orthopedic surgeons in their practice. Through its dedication to research and development, Paragon 28 aims to provide high-quality solutions that address various pathological conditions in the foot and ankle, enhancing both the effectiveness of surgical procedures and patient recovery.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSEFNA) to Zimmer Biomet Holdings, Inc. NYSE: ZBHNYSEZBH)
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSEFNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in cash is fair to Paragon 28 shareholders. Paragon 28 shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $1.00 per share in cash if certain revenue milestones are achieved.
Zimmer Biomet agrees to acquire Paragon 28 for $1.1 billion, with a non-tradeable CVR up to $1 per share. Deal expected to close in first half of 2025.
Paragon 28, Inc. (NYSEFNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024.
Paragon 28, Inc. (NYSEFNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Chadi Chahine, CFO & EVP of Supply Chain Operations, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time.
Paragon 28, Inc. (NYSEFNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Paragon 28, Inc. (“Paragon 28” or “the Company”) (NYSEFNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
LOS ANGELES, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Paragon 28, Inc. (“Paragon 28” or “the Company”) (NYSEFNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSEFNA) on behalf of purchasers of Paragon 28 securities between May 5, 2023 and September 20, 2024, inclusive (the “Class Period”).
NEW YORK, Nov. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSEFNA) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Paragon 28 common stock between May 5, 2023 and September 20, 2024, both dates inclusive (the “Class Period”). Investors have until November 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
PHILADELPHIA, Nov. 23, 2024 (GLOBE NEWSWIRE) -- Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSEFNA) on behalf of purchasers of Paragon 28 securities between May 5, 2023 and September 20, 2024, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Paragon 28 To Contact Him Directly To Discuss Their Options
NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSEFNA) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Paragon 28 common stock between May 5, 2023 and September 20, 2024, both dates inclusive (the “Class Period”). Investors have until November 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Paragon 28 To Contact Him Directly To Discuss Their Options
Paragon 28, Inc. (NYSEFNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO, and Chadi Chahine, CFO, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain Time.
Paragon 28, Inc. (NYSEFNA) (“Paragon 28” or "Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance.
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSEFNA) in the United States District Court for the District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Paragon 28 common stock between May 5, 2023 and September 20, 2024, both dates inclusive (the “Class Period”). Investors have until November 29, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the November 29, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired Paragon 28, Inc. (“Paragon 28” or the “Company”) (NYSEFNA) securities during the period of May 5, 2023 through August 8, 2024, inclusive (“the Class Period”).
